Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Pericyte cells become key players in shaping blood flow in the brain

Cells in the brain called pericytes that have not been high on the list of targets for treating diseases like Alzheimer's may play a more crucial role in the development of neurodegenerative diseases than has been realized.

18 Nov 2010

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

The biotech companies PHARNEXT and BIOSYSTEMS INTERNATIONAL, the Bordeaux Hospital where CMRR is located, the university Bordeaux Segalen and Inserm (the center U897 "Epidemiology and Biostatistics") have joined forces to carry out the DIPPAL2i project. This innovative research and industrial development project is targeting Alzheimer's disease (AD) and has attracted significant financial support from OSEO (the French state innovation agency).

18 Nov 2010

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Scientists are reporting that variants of a drug already approved for treating multiple sclerosis show promise as a long sought treatment for victims of bioterrorist attack with botulinum neurotoxin which is 10,000 times deadlier than cyanide and the most poisonous substance known to man.

18 Nov 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010

DiaGenic receives 92,738,974 shares in subsequent offering

Preliminary counts indicate that DiaGenic has received subscriptions for approximately 92,738,974 shares in the subsequent offering closed yesterday.

18 Nov 2010

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.

18 Nov 2010

State-of-the-art imaging system helps locate and count myriad connections between brain nerve cells

Researchers at the Stanford University School of Medicine, applying a state-of-the-art imaging system to brain-tissue samples from mice, have been able to quickly and accurately locate and count the myriad connections between nerve cells in unprecedented detail, as well as to capture and catalog those connections' surprising variety.

18 Nov 2010

Researchers find clue behind dementia development

Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.

18 Nov 2010

Cigarette smoke, automobile exhaust and french fries increase risk of developing Alzheimer's disease

There is growing evidence that exposure to a group of chemicals known as type-2 alkenes -- which are found in the smoke inhaled from cigarettes, the exhaust of automobiles and even in French fries - can increase the chances of developing Alzheimer's disease and other neurological conditions such as Parkinson's disease.

18 Nov 2010

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

18 Nov 2010

5-lipoxygenase protein modulates amyloid beta formation linked to Alzheimer's disease

A protein known to exist in the brain for more than 30 years, called 5-lipoxygenase, has been found to play a regulatory role in the formation of the amyloid beta in the brain, the major component of plaques implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.

18 Nov 2010

Imec and PEIRA develop platform for in-vitro study of brain tissue

The nanoelectronics research centre imec and Peira, a Belgium-based manufacturer of pharmaceutical and chemical research instruments, jointly developed an innovative slice-tilting instrument for in-vitro research on brain tissue. The new tool enables long-term studying of brain cultures through electronic stimulation and read-out, essential in getting insight into the functioning of the brain.

17 Nov 2010

New slice-tilting instrument for in-vitro research on brain tissue

17 Nov 2010

Survey on palliative care for patients with dementia

A new national survey conducted by researchers from Indiana University and the Regenstrief Institute has found that while palliative care may be available for those with dementia, there are significant barriers to providing or receiving services to relieve the pain, eating difficulties and other symptoms associated with dementia.

17 Nov 2010

Adult children of mothers with Alzheimer's at increased risk

A family history of Alzheimer's disease significantly increases the risk for developing this disorder, but a new study in Biological Psychiatry suggests that which of your parents has the disease is very important.

17 Nov 2010

New educational campaign provides information to Alzheimer's caregivers

More than five million people in the United States (U.S.) have Alzheimer's disease (AD), a progressive and devastating condition that also impacts millions of more people who love and care for these patients. Last year in the U.S., the 11 million unpaid caregivers for patients with Alzheimer's or another dementia provided 12.5 billion hours of care.

17 Nov 2010

Structural imaging techniques can help identify risk for developing Alzheimer's disease

New results from a study by neuroscientists at Rush University Medical Center suggest that people at risk of developing Alzheimer's disease exhibit a specific structural change in the brain that can be visualized by brain imaging. The findings may help identify those who would most benefit from early intervention.

17 Nov 2010

Specific brain changes suggest new therapeutic targets for Alzheimer's disease

New studies identify brain changes in people with Alzheimer's disease. The results give researchers a greater understanding of the disease and may help at-risk individuals by improving early detection. New animal research also shows a novel approach to Alzheimer's vaccine design that may avoid dangerous side effects. These new results were reported at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

17 Nov 2010

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

PrecisionMed Inc. today announced at the Society for Neuroscience annual meeting in San Diego, enrollment of the first subject into the PrecisionMed Multiple Sclerosis (MS) Registry. The PrecisionMed MS Registry is a biological sample bank of DNA and serial RNA, CSF, serum and plasma associated with serial clinical testing utilizing PrecisionMed's clinical data procurement and storage capabilities.

17 Nov 2010

Synexus to develop effective clinical trials for Mild cognitive impairment

Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.

From AES - Accelerated Enrollment Solutions 16 Nov 2010

Alzheimer's Disease News and Research

Further Reading

Pericyte cells become key players in shaping blood flow in the brain

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

DiaGenic receives 92,738,974 shares in subsequent offering

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

State-of-the-art imaging system helps locate and count myriad connections between brain nerve cells

Researchers find clue behind dementia development

Cigarette smoke, automobile exhaust and french fries increase risk of developing Alzheimer's disease

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

5-lipoxygenase protein modulates amyloid beta formation linked to Alzheimer's disease

Imec and PEIRA develop platform for in-vitro study of brain tissue

New slice-tilting instrument for in-vitro research on brain tissue

Survey on palliative care for patients with dementia

Adult children of mothers with Alzheimer's at increased risk

New educational campaign provides information to Alzheimer's caregivers

Structural imaging techniques can help identify risk for developing Alzheimer's disease

Specific brain changes suggest new therapeutic targets for Alzheimer's disease

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

Synexus to develop effective clinical trials for Mild cognitive impairment

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News